Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease.  Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases.  Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics. 

Biotechnology

Volastra

Volastra's headquarters in Boston, MA, United States

Scott Drutman

Linda Lee

Timothy Bowler

Rachel Zolot Schwartz

Michael Su

Hans Clevers

Olivier Elemento

Karen Vousden

Samuel Bakhoum

Amy Schulman

Herald Varmus

Luc Dochez

Lewis Cantley

Sandi Peterson

David Pellman

Duane Compton

David Baltimore

Gerard Evan

Tarun Kapoor

Arjun Balar

Stefan Vitorovic

Description

People (2)

Michael Su

Jianmin Mao

Jobs